Shop by goal
Popular compounds
Research resources
Recently viewed
Why “Reta” Searches Are Surging in the USA: A 2026 Search-Trend Report
Short answer: US search interest in retatrutide - and its nickname “reta” - has gone from near-zero before mid-2023 to what Google Trends labels a “Breakout” query (its tag for searches growing faster than +5,000% off a tiny base). The surge tracks Eli Lilly’s Phase 2 data and the wider GLP-1 cultural moment. Important caveat up front: this measures search curiosity - what Americans are typing into Google - not clinical demand, sales, approval, or any endorsement of human use. New-U supplies retatrutide (catalogued as Retatrutide) strictly as a research compound for laboratory use.
If you follow peptide search data, one term has bent the curve harder than almost anything else in the category since 2023: retatrutide . On Google Trends for the United States, the query was essentially flat - indistinguishable from noise - through 2022 and into early 2023, then climbed steeply through the back half of 2023 and held an elevated plateau into 2026. Google’s own algorithm flags both retatrutide and the shorthand reta as Breakout terms, the label it reserves for searches growing more than +5,000% from a near-zero starting point.
How to read a “Breakout” figure. Google Trends reports relative search interest on a 0–100 scale, not raw query counts, and a percentage like “+5,000%” or any specific number you may have seen quoted depends entirely on the comparison window and the exact query. When a term starts from almost nothing, even modest absolute volume produces an enormous percentage. The honest takeaway is directional: retatrutide went from unknown to widely searched in the US in under two years. For the live figure, open the Google Trends link above and set your own date range.
What the trend actually shows
Three patterns stand out in the US search data for retatrutide:
What is driving the surge
The proximate cause is well documented. In June 2023 the New England Journal of Medicine Phase 2 data reported a mean weight reduction of roughly 24% over 48 weeks at the highest dose - the largest body-composition effect ever recorded in an incretin-class trial. That single number drove a wave of coverage, and the search curve followed it almost exactly.
But retatrutide didn’t rise in a vacuum. It rode the broader GLP-1 wave - the same cultural moment that made “Ozempic” a household word and pushed semaglutide and tirzepatide searches to sustained highs. Where retatrutide differs is mechanism: it is the first triple agonist (GLP-1 / GIP / glucagon) to reach late-stage trials, and the novelty of “the next one after Mounjaro” is itself a search driver. We map the full pipeline in Beyond GLP-1: the next obesity research wave.
How “reta” compares to the rest of the incretin class
Search interest, regulatory status and mechanism don’t move together. Here is how the three most-searched incretin terms line up in the US:
The key point American searchers miss: retatrutide is a different regulatory category from Ozempic or Mounjaro. The first two are FDA-approved medicines. Retatrutide is not approved anywhere, which is exactly why no US pharmacy or clinic can sell it and why the only lawful route is research-use sourcing. For the wider legal map, see Peptides & the FDA and Are peptides legal?.
What the search data does not mean
This is the part most “trending peptide” write-ups skip. A rising search line is a measure of attention , not of any of the following:
We labour this point because the gap between “everyone is searching for it” and “it is proven and approved” is exactly where mis-selling happens. Treat any US-facing site claiming “FDA-approved retatrutide” or “prescription reta for weight loss” as a red flag - it does not exist.
How US researchers source retatrutide
Because retatrutide is unapproved, it is supplied in the US as a research chemical for laboratory use - not as a medicine. A US-facing supplier worth trusting should:
On our catalogue, retatrutide is listed as Retatrutide - the same 39-amino-acid LY3437943 sequence, supplied as a research compound, independently HPLC-tested to >99% by Janoshik Analytics and Freedom Diagnostics with a per-batch CoA. US researchers can review the commercial-intent overview at our retatrutide buy landing or the dedicated Buy Retatrutide in the USA page, and the broader US catalogue at Buy Peptides in the USA.
The bigger picture: a category-wide trend
Retatrutide’s breakout is the sharpest example, but it is part of a broader US pattern - rising research-compound search interest across the incretin class and beyond. We track that wider picture in our country report, Research Peptide Search Demand in the USA: 2026 Trend Report, and compare it with the parallel UK surge in Retatrutide Search Demand in the UK and the dual-agonist story in Tirzepatide Search Demand in the USA.
Frequently Asked Questions
Is search interest in retatrutide really rising in the USA? Yes. Google Trends classifies retatrutide and “reta” as Breakout queries in the US - its label for searches growing faster than +5,000% from a near-zero base. It barely registered before mid-2023. This measures search curiosity, not clinical demand or any endorsement of human use.
What is driving the surge? The largest single driver was the June 2023 Phase 2 publication reporting ~24% mean weight reduction at the top dose. Media coverage and the wider GLP-1 moment amplified it.
Does rising search interest mean retatrutide is approved or safe? No. Retatrutide has no marketing authorisation anywhere and is still in Phase 3 trials. Search popularity says nothing about approval, safety or efficacy. New-U supplies it strictly as a research compound, not for human use.
How do US researchers source retatrutide? From research-compound suppliers that label material research use only, publish a per-batch CoA with HPLC purity and mass-spec identity, and make no human-use claims. No US pharmacy can sell it.
Related Reading
Primary sources & further reading
Search-interest figures are directional and depend on the query and date range chosen in Google Trends; New-U is not affiliated with Google or these organisations and links carry no endorsement. Nothing here is medical advice.
From the Lab - Peptides on LinkedIn & Facebook
Lab-Verified Retatrutide for US Researchers
New-U Research Compounds ships retatrutide (catalogued as Retatrutide) in sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a per-batch Certificate of Analysis. Tracked US delivery, free over $300. Research use only - not for human consumption.
Research-grade · >99% HPLC purity · COA per lot
Buy Retatrutide from New-U Research Compounds
Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io